Reuters news agency reports that the Department of Justice started an investigation into Sanofi SA And GlaxoSmithKline on whether they knew about the potential presence of a probable carcinogen, N-nitrosodimenthylamine (NDMA), in the heartburn drug Zantac and ranitidine.[i] This is a civil investigation under the False Claims Act[ii] which could potentially result in multimillion-dollar fines. Both companies reported this to the Securities Exchange Commission, as legal action may affect their stock prices. In February, Sanofi took a $186 write down for Zantac losses.
FDA RECALL DUE TO CANCER CONCERNS
The FDA was the first federal agency to act by issuing a complete recall in April 2020.[iii] The FDA’s own internal investigation found unacceptably high levels of the cancer-causing NDMA molecule. Notably, there are early medical studies showing the NDMA molecule urinary output. GSK challenged the results but never notified the FDA. It also appears that GSK had done metabolite studies on Zantac users which could have measured NDMA levels in urine, but never measured it.
CANCER VICTIMS FILING CLAIMS AND LAWSUITS
Prior medical studies linked digestive, urinary, and breast cancers to the NDMA molecule. Based on the FDA’s Zantac and Ranitidine recall, cancer victims are filing lawsuits. Our firm is screening hundreds of cancer victims. Our evaluations are based on the many cancer medical studies involving NDMA exposure in combination with the length of use, age at diagnosis, and pre-existing cancer factors. If you or a loved one has been a victim of cancer, please call litigation partner David B. Rheingold for a free, confidential consultation. His drug litigation experience against large companies will help them evaluate any potential claims you may have.